Albeit still a relatively small business (£5.1m mrkcap), Verici Dx certainly punches above it weight.
Today announcing that in Q4'26, it plans to launch a new "1st-in-class" genetic RNA blood test TranscripTx.
This diagnostic is specifically designed for the transplant community and can identify key variations in a person’s genes that are known to impact biological processes relevant to transplant patients. Information that may accelerate new drug development, inform ongoing clinical trials and improve medical management protocols.
CEO Sara Barrington commenting: "This test underscores our commitment to pioneering personalised diagnostics in transplantation, maximising the strategic value of our clinical data while offering a vital new resource for therapeutic development and patient care."
Disclosure: Verici Dx is a Vox Markets client